New approaches might lower drug prices

09/26/2013 | Reuters

Targeted clinical trials, wherein compounds are tested on patients with specific genetic traits, might lower development costs and subsequent prices for promising immunotherapies. Drugmakers are also experimenting with combinations of existing treatments that might cost less than single compounds. The FDA has become more flexible, speeding the approval process for drugs designated as breakthroughs and giving others priority review.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI